Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Disc Medicine, Inc. - Common Stock (NQ: IRON ) 50.82 +2.02 (+4.14%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Disc Medicine, Inc. - Common Stock < Previous 1 2 Next > Disc Medicine to Participate in Upcoming Investor Conferences August 30, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces Underwritten Offering of Common Stock June 14, 2024 From Disc Medicine Inc Via GlobeNewswire NASDAQ:IRON Shareholder Notice: Investigation over Potential Wrongdoing at Disc Medicine Opco Inc December 08, 2023 San Diego, CA -- (SBWIRE) -- 12/08/2023 -- Certain directors of Disc Medicine Opco Inc are under investigation over potential breaches of fiduciary duties. Via SBWire Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress June 14, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress May 14, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference May 13, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) April 01, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 21, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 March 06, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer February 26, 2024 Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches From Disc Medicine Inc Via GlobeNewswire Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease February 20, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera February 09, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer February 07, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board December 20, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting December 11, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting December 11, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin November 14, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Participate in Upcoming Investor Conferences November 08, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates November 02, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce October 23, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers October 03, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera September 20, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine to Participate in Upcoming Investor Conferences August 30, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update August 11, 2023 From Disc Medicine Inc Via GlobeNewswire Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA) July 27, 2023 From Disc Medicine Inc Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.